The development of novel LTA4H modulators to selectively target LTB4 generation by Low, Caroline M. et al.
1Scientific RepoRts | 7:44449 | DOI: 10.1038/srep44449
www.nature.com/scientificreports
The development of novel LTA4H 
modulators to selectively target 
LTB4 generation
Caroline M. Low1, Samia Akthar2, Dhiren F. Patel2, Stephan Löser2, Chi-Tung Wong3, 
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The pro-inflammatory mediator leukotriene B4 (LTB4) is implicated in the pathologies of an array of 
diseases and thus represents an attractive therapeutic target. The enzyme leukotriene A4 hydrolase 
(LTA4H) catalyses the distal step in LTB4 synthesis and hence inhibitors of this enzyme have been 
actively pursued. Despite potent LTA4H inhibitors entering clinical trials all have failed to show efficacy. 
We recently identified a secondary anti-inflammatory role for LTA4H in degrading the neutrophil 
chemoattractant Pro-Gly-Pro (PGP) and rationalized that the failure of conventional LTA4H inhibitors 
may be that they inadvertently prevented PGP degradation. We demonstrate that these inhibitors do 
indeed fail to discriminate between the dual activities of LTA4H, and enable PGP accumulation in mice. 
Accordingly, we have developed novel compounds that potently inhibit LTB4 generation whilst leaving 
PGP degradation unperturbed. These novel compounds could represent a safer and superior class of 
LTA4H inhibitors for translation into the clinic.
Leukotriene A4 hydrolase (LTA4H) is an enzyme that classically functions as an epoxide hydrolase to generate 
leukotriene B4 (LTB4) from leukotriene A4 (LTA4)1,2. This activity operates within an intracellular compartment 
and is predominantly a function of leukocytes. LTB4 is an extremely pro-inflammatory lipid mediator that can 
exert its activity by binding to receptors BLT1 or BLT23. LTB4 can drive the recruitment and activation of an array 
of cells including neutrophils and is thus implicated in protection against invading micro-organisms but also in 
the pathology of an array of diseases4–8.
Recently, we identified a secondary anti-inflammatory activity for LTA4H whereby it functions as an amin-
opeptidases to degrade the tripeptide Pro-Gly-Pro (PGP)9. PGP is a neutrophil chemoattractant derived from 
extracellular matrix (ECM) collagen via the sequential enzymatic activity of matrix metalloproteinases and pro-
lylendopeptidase10. PGP functions as a neutrophil chemoattractant by mimicking key sequences found in glu-
tamic acid, leucine, arginine+ (ELR+) chemokines and binding to CXCR1/211. Since neutrophils are themselves 
a prominent source of the enzymes that generate PGP, it is thought that this pathway can drive a self-sustaining 
vicious circle of inflammation if left unchecked12. We have demonstrated that PGP is readily degraded during 
episodes of acute pulmonary inflammation by extracellular LTA4H to facilitate the resolution of neutrophilic 
inflammation, and failure of this system culminated in augmented and prolonged inflammation with exacerbated 
pathology and illness9,13.
Significant quantities of PGP are found in patients with chronic neutrophilic lung diseases such as chronic 
obstructive pulmonary disease (COPD), Cystic Fibrosis (CF) and bronchiolitis obliterans syndrome (BOS), 
peaking with exacerbation of disease and inversely correlating with lung function10,11,14–17. Accordingly, it seems 
that the LTA4H-PGP degradation pathway is perturbed in these chronic diseases to enable PGP to accumu-
late and drive inflammation9,15,18. Together, these studies highlight the critical importance of the secondary 
PGP-degrading activity of LTA4H.
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LTA4H therefore represents a highly unusual enzyme with dichotomous and directly opposing pro- and 
anti-inflammatory activities that dictate the amplitude and persistence of neutrophilic inflammation19. The 
enzyme itself is folded into 3 domains, which manifest as N-terminal, catalytic and C-terminal domains20. The 
interface of these domains forms an L-shaped cavity where the active site of the enzyme is located. The opening 
part of this cavity, near the protein surface, is wider and highly hydrophilic before narrowing at the site of the 
catalytic zinc into a predominantly hydrophobic tunnel that penetrates deeper into the protein. The wider hydro-
philic part of the cavity is the site of peptide binding, whereas LTA4 occupies the entire cavity with its epoxide 
coordinating with the zinc and its long hydrophobic tail extending down into the apolar tunnel. It is clear there-
fore that the opposing activities of LTA4H reside within distinct yet overlapping active sites, with specific amino 
acid residues required for each21,22.
There has been significant interest from pharmaceutical companies to target LTA4H therapeutically to alleviate 
LTB4-mediated pathologies, but despite the generation of several excellent inhibitors, these drugs have failed to 
demonstrate clinical efficacy or have been withdrawn from trials owing to deleterious side effects23,24. It is feasible 
that the lack of success of these compounds may be due to their failure to distinguish between the opposing roles 
of LTA4H and thus inadvertently prevent PGP degradation. Searle/Pharmacia developed the potent, orally active 
inhibitor SC567461A that entered clinical trials for inflammatory bowel disease, but was withdrawn owing to 
adverse outcomes25–27. DeCODE pharmaceuticals subsequently utilized a fragment based drug discovery pro-
gram to identify inhibitors of LTA4H, leading to the development of the potent, orally active compound DG-051 
that entered phase IIa clinical trials for myocardial infarction and stroke before further development being pre-
cluded28–30. More recently, Johnson & Johnson developed potent, orally active benzothiazole derivatives as LTA4H 
inhibitors31–33 leading to the assessment of JNJ-40929837 in a bronchial allergen challenge model of asthma24. 
Despite JNJ-40929837 demonstrating clear target engagement and reducing LTB4, this drug again failed to show 
any clinical benefit over placebo24.
Some studies have previously proposed that it is feasible to develop compounds that can selectively distinguish 
between the dual activities of LTA4H. Lai and colleagues suggested that diphenyl ether derivatives were capable 
of augmenting aminopeptidase activity against a synthetic Ala-p-nitroanilide substrate34. Accordingly, Paige and 
Shim have demonstrated that 4-methoxy diphenylmethane (4-MDM) augmented the aminopeptidase activity 
of LTA4H and conferred therapeutic benefit in murine models of emphysema35,36. Conversely, Haeggstrom and 
colleagues have suggested that it is feasible to selectively inhibit the epoxide hydrolase activity whilst leaving 
the aminopeptidase activity unperturbed, demonstrating that the molecule 4-(4-benzylphenyl) thiazol-2 amine 
(ARM1) could inhibit LTB4 generation without affecting PGP degradation37.
In this study, we have utilized robust, physiologically relevant assays to provide a definitive side-by-side com-
parison of existing classes of LTA4H modulators and develop novel selective compounds. We demonstrate that 
existing LTA4H inhibitors that have entered the clinic are equipotent at inhibiting both LTB4 generation and PGP 
degradation and in vivo administration can consequently result in PGP accumulation. We highlight the necessity 
of using the physiological substrate, PGP, when evaluating the aminopeptidase activity of LTA4H; with diphenyl 
ether derivatives failing to boost PGP cleavage as has been reported with an alternative Ala-p-nitroanilide sub-
strate. Finally, we have developed two distinct chemical series of compounds that can selectively inhibit LTB4 
generation with a selectivity that is superior to that of ARM1. These novel compounds could form the basis for 
the development of selective and safer therapeutics for targeting LTA4H in a broad array of disease modalities.
Results
A rational approach to selective LTA4H inhibitor design. Previous studies that have aimed to develop 
potent LTA4H inhibitors have largely failed to consider the physiological significance of the recently identified 
anti-inflammatory aminopeptidase activity. It is apparent that the two activities of LTA4H occur via distinct but 
overlapping active sites, both located in a deep L-shaped cleft. One arm of this cleft is narrow and hydrophobic 
(Site A; Fig. 1a) and the other contains the zinc-binding site (Site B; Fig. 1a). LTA4 fills the entire cavity, with its 
hydrophobic tail buried in one arm and the zinc chelated to the epoxide in the other arm (Fig. 1a). In contrast, 
aminopeptidase PGP-degrading activity appears confined to the zinc-containing arm (Fig. 1b). We hypothesized 
that whilst conventional LTA4H inhibitors would occupy both sites it would be preferable to develop molecules 
to bind to one of the two overlapping binding sites (Site A) present in LTA4H, leaving Site B free to bind PGP 
(Fig. 1c). This should block detrimental hydrolase activity, whilst preserving beneficial peptidase function.
Conventional LTA4H inhibitors that have entered the clinic are non-selective and inhibit PGP 
degradation. To validate our hypothesis that conventional LTA4H inhibitors fail to distinguish between the 
dual activities of the enzyme, we synthesized SC57461A, DG-051 and JNJ-40929837 and assessed their capacity 
to inhibit LTB4 generation and PGP degradation. In keeping with previous literature, all were potent inhibitors 
of LTA4H epoxide hydrolase activity in a murine neutrophil-based assay (Table 1; Fig. 1d for representative IC50 
curve for DG-051). However, each of these compounds was also comparably potent at inhibiting the aminopep-
tidase activity of recombinant LTA4H against the PGP substrate (Table 1; Fig. 1e for representative IC50 curve 
for DG-051). This lack of selectivity can be rationalized by examining published X-ray data of LTA4H bound 
to SC57461A (3U9W.pdb) and DG-051 (3FH7.pdb) with that of 1-{4-oxo-4-[(2S)-pyrrolidin-2-yl]butanoyl}- 
L-proline (OBP-Pro), a stable PGP analogue (4MS6.pdb). In all cases the structure of the protein is highly 
conserved (rms 0.28–0.35 Å over 611 atoms) and focussing on the active site of the enzyme shows that both 
SC57461A (Fig. 1f) and DG-051 (Fig. 1g) encroach into the zinc binding arm (Site B) that OBP-Pro, and by 
analogy PGP, occupies. Docking JNJ-40929837 into the same site (Fig. 1h) demonstrates that this compound fills 
both arms, again suggesting it will impede PGP binding. It has previously been demonstrated that oral admin-
istration of SC57461A or a JNJ-40929837 derivative to naïve mice resulted in a potent inhibition of LTB4 gen-
eration in an ex vivo whole blood assay25,31. Importantly, we demonstrate that a comparable protocol, whereby 
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Figure 1. LTA4H inhibitors to have entered the clinic are non-selective and inhibit PGP degradation  
in vitro and in vivo. Schematic representation of the binding site of LTA4H showing the relative positions 
occupied by LTA4 (a) and PGP (b). (c) Proposed solution for a new compound that sits in the narrow arm 
occupied by the hydrophobic tail of LTA4, (Site A) blocking its hydrolysis, but retaining ability to cleave the 
tripeptide PGP (Site B). The capacity of DG-051 to inhibit LTA4H epoxide hydrolase (LTB4 generation; (d)) and 
aminopeptidase activities (PGP degradation; (e)). Overlay of the X-ray structures of ligand-LTA4H structures 
of (f) SC57461 (blue; 3U9W.pdb) and (g) DG-051 (pink; 3FH7.pdb) with that of the stable PGP analogue OBP-
Pro (white, 4MS6.pdb). The protein surface is coloured by amino acid hydrophobicity from most hydrophobic 
(orange) to hydrophilic (blue) through white regions. (h) JNJ-40929837 (green) was docked into the protein 
with Autodock Vina. Mice were orally administered SC57461A (i and j) or JNJ-40929837 (k and l) and serum 
aminopeptidase activity (i and k) or absolute PGP concentrations (j and l) were determined. IC50 curves were 
generated from 3 technical replicates at each concentration of test compound and at least 2 biological replicates. 
Data for in vivo studies (i–l) are representative of 2 experiments with 5 mice per group. Results depicted as 
mean ± SEM. *P < 0.05, **P < 0.01 using Mann–Whitney statistical test.
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SC57461A or JNJ-40929837 are orally administered to naïve mice, also potently abrogates serum aminopeptidase 
PGP-degrading activity (Fig. 1i and k, respectively) and leads to serum accumulation of PGP (Fig. 1j and l, respec-
tively). These studies highlight the potential inherent risk of these potent, yet non-selective, LTA4H inhibitors.
Diphenyl ether derivatives fail to augment LTA4H aminopeptidase activity when utilizing the 
physiological substrate PGP. Previous reports have cited the potential of simple diphenyl ether derivatives 
to enhance aminopeptidase activity in assays using chromogenic synthetic peptide substrates34. The compound 
4-MDM exemplifies this class of compounds, being demonstrated to augment aminopeptidase activity versus an 
Ala-p-nitroanilide substrate with an AC50 of 50 μ M35. In our hands, whilst 4-MDM did promote aminopeptidase 
activity versus an Ala-p-nitroanilide substrate, this augmentation was not observed when utilizing the physiolog-
ical substrate PGP; with modest inhibition even apparent (Table 1). The size and structural differences between 
PGP and Ala-p-nitroanilide substrates may result in their altered occupancy and positioning within the active site 
of LTA4H, and rationalize the differences observed in the behaviour of 4-MDM. However, these studies clearly 
demonstrate the importance of utilizing a physiological substrate rather than one that facilitates high throughput 
screening and suggest that diphenyl ether derivatives do not offer a promising chemical starting point as a gener-
ation of selective LTA4H modulators.
Development of selective LTA4H inhibitors to specifically target LTB4 generation. Haeggstrom 
and colleagues recently identified ARM1 as a potential selective LTA4H inhibitor, with the capacity to inhibit LTB4 
generation without perturbing PGP hydrolysis. They demonstrated that ARM1 efficiently inhibited LTB4 pro-
duction by neutrophils with an IC50 of 0.5 μ M without significantly compromising PGP degradation37. In our cell 
based system, ARM1 exhibited a comparable capacity to inhibit LTB4 generation (Table 1). However, whilst we 
did confirm a distinct selectivity of ARM1 in inhibiting the epoxide hydrolase activity over the aminopeptidase 
activity, this compound was, in our hands, capable of inhibiting PGP degradation with an IC50 of around 9.1 μ M 
(Table 1). In publishing the X-ray crystallography structure of ARM1 within the active site of LTA4H, the authors 
report two potential orientations of the compounds located within Site A portraying some fluidity in binding. 
Our docking analysis of ARM1 within the active site of LTA4H revealed one of six poses where the compound 
sits in the peptide binding site (Supplementary Figure S1) – which may rationalize the partial inhibition of this 
activity.
Resveratrol-based compounds to selectively target LTA4H. A published X-ray structure of LTA4H 
(3FTX.pdb) shows two different molecules simultaneously bound in each arm of the active site (Fig. 2a). A 
Compound
Epoxide Hydrolase 
IC50 ± SEM (nM)
Aminopeptidase 
IC50 ± SEM (nM)
SC57461A 
110 ± 23.5 74 ± 7.3
DG-051 
680 ± 10.0 150 ± 19.4
JNJ- 40929837 
9.0 ± 0.09 9.4 ± 1.3
4-MDM 
48,900 ± 9,538 75,210 ± 9,752
ARM1 
600 ± 66.2 9,110 ± 1,092
Table 1.  Effect of LTA4H inhibitors to have entered the clinic and purportedly selective modulators on 
inhibition (IC50) of the epoxide hydrolase (LTB4 generation) and aminopeptidase (PGP degradation) 
activities of LTA4H in our assays, as described in Materials and methods. IC50 curves were generated from 3 
technical replicates at each concentration of test compound and at least 2 biological replicates. Results depicted 
as mean ± SEM.
www.nature.com/scientificreports/
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molecule of 2H-resveratrol solely occupies our target site (Site A), whilst one of bestatin – a known peptidase 
inhibitor, occupies the Zn catalytic site (Site B). The molecule resveratrol (compound 1) occupies the same region 
of the active site (Site A) as 2H-resveratrol, but with its double bond reducing flexibility (3FTS.pdb). In this 
structure, the R2 phenol hydroxyl of resveratrol makes a key interaction with a hydrophilic patch on the enzyme, 
encompassing Ser-379, Lys-364 and Asp-312. Thus resveratrol (compound 1) seemingly represented a rational 
starting point for the development of a novel selective LTA4H inhibitor. In accordance with the binding studies, 
resveratrol (compound 1) exhibited minimal inhibition of PGP degradation, with negligible inhibition observed 
at a concentration of 100 μ M (Table 2a). Furthermore, this compound exhibited a modest inhibition of LTB4 
generation and thus displays some potential to distinguish between the two functions of the enzyme with biased 
inhibition of the epoxide hydrolase activity (Fig. 2b and Table 2a). An iterative approach of targeted drug design 
and structure activity relationship studies (SAR) was subsequently utilized to develop compounds based upon the 
resveratrol core that would exhibit superior inhibition of LTA4H epoxide hydrolase activity whilst maintaining 
selectivity.
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Figure 2. Compounds with a resveratrol core are selective epoxide hydrolase inhibitors. (a) LTA4H contains 
two overlapping binding Sites A and B with previous X-ray crystallography studies revealing that two small 
molecules are capable of binding in each of the sites simultaneously (3FTX.pdb). Peptidase inhibitor Bestatin 
occupies Site B and 2H-Resveratrol sits in Site A. The protein surface is coloured by amino acid hydrophobicity 
from most hydrophobic (orange) to hydrophilic (blue) through white regions. LTA4H epoxide hydrolase activity 
(b,c and f) and aminopeptidase activity (d and g) are presented following treatment with resveratrol (compound 
1; b), compound 5 (c and d) and compound 9 (f and g). (e) Site A with docked pose of pinostilbene (compound 
5; grey) overlaid on the X-ray structure of 2H-resveratrol bound to LTA4H (blue; 3FTS.pdb). The protein surface 
is coloured by amino acid hydrophobicity from most hydrophobic (orange) to hydrophilic (blue) through 
white regions. The methyl ether exploits a hydrophobic patch in Site A, an interaction that is not favoured for 
Resveratrol and accounts for the increase in activity of compound 5 compared to Resveratrol. IC50 curves were 
generated from 3 technical replicates at each concentration of test compound and at least 2 biological replicates. 
Results depicted as mean ± SEM.
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Changing the configuration of the double bond from trans- (resveratrol; compound 1) to cis- (compound 2) 
alters both the distance and relative dispositions of the two aromatic rings but seemingly had minimal impact 
on the compound’s capacity to inhibit epoxide hydrolase or aminopeptidase activities of LTA4H (Table 2a). The 
results of docking experiments suggest both cis- (compound 2) and trans-resveratrol (compound 1) occupy the 
desired region (Site A) of the active site with one of the phenol hydroxyls (R2) of both compounds forming an 
identical interaction with a hydrophilic patch on the enzyme. Blocking all three hydroxyls of trans-resveratrol 
with methyl ethers (compound 3) or acetyl groups (compound 4) modestly reduced the capacity to inhibit 
LTB4 generation (Table 2a). However, methylation of a single hydroxyl (R1) gives a compound with significantly 
increased capacity to inhibit LTB4 generation (compound 5. Figure 2c and Table 2a), whilst still leaving amino-
peptidase activity largely unperturbed (Fig. 2d and Table 2a). Docking this molecule into Site A shows that this 
can be attributed to an interaction with a hydrophobic patch that cannot be exploited by the polar R1 OH of 
resveratrol (Fig. 2e).
Further modification of compound 5 confirmed that the double bond between the two aromatic rings was 
not essential for inhibition of epoxide hydrolase activity (compound 6; Table 2b). Moreover increasing the size 
of the alkyl ether substituent at R1 from methyl to ethyl (compound 7) did not offer any advantage in promoting 
LTB4 inhibitory capacity (Table 2b). Exploring other regioisomers of compound 6 (Table 2b) highlighted that the 
positions of the phenolyic hydroxyl groups were not optimal. For example, moving the phenol hydroxyl from the 
R5- to the R4-position (compound 8) had modest impact on its capacity to inhibit LTB4 generation, but reloca-
tion of the hydroxyl to the R3-position (compound 9) augmented the LTB4 inhibitory capacity of the compound 
10-fold (IC50 0.5 μ M; Fig. 2f and Table 2b), whilst still leaving the aminopeptidase PGP-degrading activity unper-
turbed (Fig. 2g and Table 2b). The origins of the augmented capacity of compound 9 to inhibit LTA4H epoxide 
Cmpd. No. R1 R2 R3
Epoxide Hydrolase 
IC50 ± SEM (μM)
Aminopeptidase 
IC50 ± SEM (μM)
1 OH OH OH 32.2 ± 5.9 > 100
2a OH OH OH 14.3 ± 2.1 85.3 ± 33.9
3 OMe OMe OMe 41.2 ± 5.5 68.8 ± 9.9
4 OCOMe OCOMe OCOMe 38.6 ± 5.9 > 100
5 OMe OH OH 3.9 ± 0.4 99.5 ± 22.6
Cmpd. No. R1 R2 R3 R4 R5
Epoxide 
Hydrolase 
IC50 ± SEM 
(μM)
Aminopeptidase 
IC50 ± SEM 
(μM)
6 OMe OH H H OH 6.4 ± 0.7 > 100
7 OEt OH H H OH 3.2 ± 0.7 > 100
8 OMe OH H OH H 1.7 ± 0.25 > 100
9 OMe OH OH H H 0.50 ± 0.04 > 100
Table 2.  Effect of (a) analogues of resveratrol (compound 1) and (b) (hydroxyphenyl)ethylphenols on 
inhibition (IC50) of the epoxide hydrolase (LTB4 generation) and aminopeptidase (PGP degradation) 
activities of LTA4H as described in Materials and methods. IC50 curves were generated from 3 technical 
replicates at each concentration of test compound and at least 2 biological replicates. Results depicted as 
mean ± SEM. aZ-isomer.
www.nature.com/scientificreports/
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hydrolase activity were explored by modelling and X-ray crystallography (Fig. 3a). The X-ray structure of LTA4H 
shows high similarity to literature examples (RMSD between 606 atom pairs is 0.204 Å). Of most note, compound 
9 has flipped within Site A of the active site of LTA4H relative to 2H-resveratrol (3FTU.pdb) so that the phenolic 
hydroxyl in the 2-position now forms a hydrogen bond with Asp-375 (Fig. 3b and c) and the two ligands are effec-
tively located head-to-tail. This pose is also present in those generated by in silico docking. Whilst 2H-resveratrol 
forms two interactions with Trp-311, one H-bond and one π -stack, these are absent in the compound 9 structure, 
where the 3-methoxy-5-phenol ring rotates to allow the phenol to H-bond to Asp-375 (Fig. 3c). Importantly, 
previous site-directed mutational interrogation of the active site of the enzyme has identified Asp-375 to be the 
only residue uniquely and absolutely required for the enzyme’s epoxide hydrolase activity38. This therefore likely 
underlies the far superior capacity of compound 9 versus 2H-resveratrol to inhibit that capacity of LTA4H to gen-
erate LTB4. Overlaying our X-ray data of compound 9 bound within the active site of LTA4H with the published 
structure of OBP-Pro (4MS6.pdb) demonstrates that compound 9 occupies our target site A, without encroach-
ing into the zinc binding arm (site B) that OBP-Pro, and by analogy PGP, occupies (Fig. 3d).
Thus compound 9 represented a chemical series with clear and rational potential to selectively inhibit the 
epoxide hydrolase activity of LTA4H. We next questioned whether this compound would exhibit a comparable 
capacity to inhibit LTB4 generation in human neutrophils. Preliminary data obtained using blood-derived neutro-
phils from two distinct donors demonstrated that compound 9 inhibited LTB4 generation with an IC50 of 2.4 μ M 
– comparing favourably with that obtained with murine cells. Furthermore, it should be stressed that human neu-
trophils produced more LTB4 on a per cell basis than mouse neutrophils in our assays, and thus all compounds 
were slightly less potent in the human system. To determine whether compound 9 possessed suitable drug-like 
properties to merit advancement, in vitro ADMET studies were performed to assess plasma protein binding, 
microsome stability and logD (Supplementary Table S1). These studies highlighted that a potential weakness of 
compound 9 was that it was readily metabolized in microsomes and would thus be readily cleared in vivo.
Isoflavone-based compounds to selectively target LTA4H. At this point it became clear that we 
needed to improve the drug-like properties of our series. Given the size restraints imposed by the binding site, 
our initial investigations focussed on identifying alternative groups to link the two aromatic rings. We found that 
amides lost all capacity to inhibit either activity but replacing the carbon adjacent to ring A with a ketone (com-
pound 10) was tolerated showing preferential inhibition of the epoxide hydrolase activity (Table 3). Moreover, 
the isoflavone daidzein (compound 11), which incorporates the structure of compound 10, was equipotent with 
its uncyclized counterpart in terms of selective inhibition of the hydrolase activity (Table 3) and represents a new 
chemotype, with the additional benefit of greatly increased metabolic stability reported (t1/2 7.75 ± 0.36 h)39. A 
survey of commercially available isoflavones rapidly identified 7,8,4′ -trihydroxyisoflavone (compound 12) with 
> 8-fold selectivity for hydrolase over peptidase inhibition (Table 3). Docking compound 12 into the active site 
of LTA4H produces poses in which the new compound occupies the same region as resveratrol and in which the 
R3 hydroxyl makes a key interaction with the same hydrophilic patch of the enzyme (Fig. 3e); and the parallel 
behaviour of the two series supports this hypothesis. In sharp contrast to 9, we determined that the isoflavone 
compound 12 showed greatly increased metabolic stability over the resveratrol series in both mouse and human 
microsomes (Supplementary Table 1).
Investigating the role of the hydroxyl substituents demonstrated that loss of the R1 and R3 hydroxyls from 
compound 12 (to give compound 13) diminished the capacity of the compound to inhibit the epoxide hydrolase 
activity of LTA4H, with docking studies suggesting that the R3 phenyl OH was no longer capable of finding the 
key binding interaction with a hydrophilic patch of the enzyme identified in the earlier structure-activity studies. 
Blocking both R3 and R2 hydroxyls by formation of the acetal (compound 14) also produced a modest reduc-
tion in hydrolase inhibition versus compound 12, whilst also increasing aminopeptidase inhibition (Table 3). 
However, replacing just the R2 hydroxyl of compound 12 with a methyl group (compound 15) gives a compound 
with increased ability to inhibit hydrolase activity, whilst showing clear selectivity versus aminopeptidase inhi-
bition (Table 3). Docking studies rationalized this enhanced inhibition of epoxide hydrolase activity, with the 
R2 methyl making an additional interaction with a hydrophobic patch within the active site, whilst still allowing 
the R3 OH to hydrogen bond to the aforementioned hydrophilic region (Fig. 3f). Importantly, docking studies 
strongly suggest that the R1 OH of compound 15 is now able to make a hydrogen bond with Asp-375 (Fig. 3f), 
further rationalizing the potency and specificity with which it is able to inhibit the epoxide hydrolase activity 
of LTA4H. Thus compound 15 offered another chemical starting point for the development of selective LTA4H 
inhibitors but with greater metabolic stability.
Discussion
LTA4H inhibitors developed by pharmaceutical companies to alleviate LTB4-mediated pathologies have demon-
strated clear target engagement, but failed to show efficacy in the clinic. In this study, we validated that clinically 
evaluated LTA4H inhibitors target both activities of the enzyme and importantly enable PGP accumulation in 
vivo, highlighting the necessity to generate selective compounds. Furthermore, we reveal that diphenyl ether 
derivatives purported to augment the aminopeptidase activity of LTA4H are ineffective when using the physio-
logical substrate PGP. Finally, we identify two distinct chemical series that can selectively inhibit LTB4 generation 
whilst maintaining PGP degradation and may offer a starting point for the development of novel, superior and 
safer LTA4H modulators.
SC57461A, DG-051 and JNJ-40929837 have all been reported as potent, selective, orally efficacious inhibitors 
of LTB4 synthesis. However, we report for the first time that these compounds are equipotent at inhibiting PGP 
degradation, and rationalized this in terms of their encroachment into the peptide binding arm of the active 
site. We have previously reported the absolute requirement of LTA4H to degrade PGP in vivo utilizing knock 
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a. b.
c. d.
e. f.
Asp375 Asp375
Compound 12 Compound 15
Compound 12 Compound 15
D375
W311
HOH 319
HOH 1001
HOH 797
HOH 624
HOH 1001
HOH 797
HOH 624
W311
D375
HOH 319
2H-Resveratrol Compound 9
Figure 3. Compounds 9 and 15 make a hydrogen bond with Asp-375 within Site A of the active site of 
LTA4H. (a) Green mesh surrounding Compound 9 (orange) shows the Fo-Fc difference map density (2σ 
level) having omitted the compound from the model. (b) Comparison of X-ray structure of 2H-resveratrol 
(blue; 3FTU.pdb) and compound 9 (bronze; our study) in Site A of LTA4H. The protein surface is coloured by 
amino acid hydrophobicity from most hydrophobic (orange) to hydrophilic (blue) through white regions. (c) 
Relative positions of 2H-resveratrol (blue) and compound 9 (bronze) showing hydrogen bonding interactions. 
2H-resveratrol H-bonds to the carbonyl of Trp-311 and 3 water molecules (pink) and its position is further 
reinforced by a π -stacking interaction with the indole of Trp-311. Compound 9 adopts a head-to-tail 
orientation such that its hydroxyl groups form H-bonds to Asp-375, key for hydrolase activity, and a single 
water molecule (orange). (d) Compound 9 (pink) does not impinge significantly on the peptidase site delineated 
by OBP-Pro (white; 4MS6.pdb) when the X-ray structures of Compound 9-LTA4H (our study) and 4MS6.pdb 
are overlaid. Best scored poses of compound 12 (e; white) and compound 15 (f; orange) docked into site A of 
LTA4H with Autodock Vina. The R2 OH of compound 12 is located in a hydrophobic region so replacing this 
group with a methyl substituent (compound 15) improves interaction with the protein. In addition, a hydrogen-
bonding interaction between the phenol of compound 15 and Asp-375 is also observed.
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out animals9,13. However, a valid caveat has been that LTA4H inhibitors may not yield comparable results to gene 
knock outs, with sufficient residual enzyme activity remaining to degrade PGP following inhibitor administra-
tion. It is telling therefore, that oral administration of SC57461A or JNJ-40929837 to naïve mice potently inhib-
ited aminopeptidase activity and led to serum accumulation of PGP. PGP is anticipated to support persistent 
neutrophilic inflammation and ensuing pathology in chronic lung diseases such as COPD, CF and BOS where it 
inversely correlates with lung function, spikes with exacerbations and is reduced with in-patient therapy10,11,14–17. 
Furthermore, chronic administration of PGP alone into the lungs of mice is sufficient to elicit an emphysema-
tous phenotype and neutralization of PGP can ameliorate cigarette smoke-induced pulmonary inflammation in 
mice11,40. Additionally, we have demonstrated that failure to degrade PGP in response to a relatively innocuous 
pulmonary bacterial challenge results in a more pronounced neutrophilic infiltrate, protease imbalance, ECM 
attack and enhanced illness and pathology – all hallmarks of aforementioned chronic lung disease characterized 
by persistent PGP13. Thus it is clearly apparent that perturbation of the LTA4H pathway in a manner that can 
facilitate PGP accumulation carries significant inherent risks. Accordingly, it is clear that we should be extremely 
vigilant to adverse effects of LTA4H inhibitors and novel selective drugs that can spare PGP degradation would 
be desirable.
More recent studies have reported the potential to pharmacologically manipulate the individual activities of 
LTA4H34–36. Indeed, 4-MDM has been reported to ameliorate disease in murine models of emphysema triggered 
by intranasal administration of elastase or long term cigarette smoke exposure by purportedly augmenting LTA4H 
aminopeptidase activity35,36. It is noteworthy however, that these studies have not assessed the capacity of 4-MDM 
to directly augment aminopeptidase activity of LTA4H against the physiological substrate PGP, instead using 
chromogenic amino acid analogues. In our hands, 4-MDM failed to augment PGP degradation, highlighting the 
importance of assaying enzyme activity using physiological, albeit more laborious, methodologies as opposed 
to those that enable high throughput screening. The success of 4-MDM in preclinical animal models, in light of 
these findings, is difficult to rationalize but could suggest an alternative peptide substrate for LTA4H or off target 
effects of 4-MDM given its likely low specificity and the substantial doses administered.
Recently, the Haeggstrom group elegantly demonstrated that the molecule ARM1 occupied the end of the 
L-shaped hydrophobic cavity, whilst still permitting a PGP analogue (OBP-Pro) to occupy the zinc binding site37. 
Accordingly, they showed that ARM1 could inhibit LTB4 generation by neutrophils with an IC50 of ~0.5 μ M, 
whilst exhibiting no inhibition of PGP degradation at a concentration of 100 μ M. In our experimental system, 
ARM1 exhibited a comparable capacity to inhibit LTB4 generation in cell based assays but also exhibited some 
capacity to inhibit PGP degradation - albeit still with marked selectivity towards inhibition of hydrolase activity. 
The discrepancy is almost certainly attributable to differing methodologies that are applied. When assessing ami-
nopeptidase activity of LTA4H versus PGP we have utilized enzyme at a concentration of 0.1 μ g/ml, in keeping 
Cmpd. No. R1 R2 R3
Epoxide Hydrolase 
IC50 ± SEM (μM)
Aminopeptidase 
IC50 ± SEM (μM)
10 34.24 ± 4.7 > 100
11 OH OH H 15.0 ± 2.3 > 100
12 OH OH OH 7.3 ± 0.8 62.7 ± 13.3
13 H OH H 48.2 ± 14.6 > 100
14 OH O-CH2-O 20.6 ± 2.4 20.6 ± 3.3
15 OH Me OH 1.2 ± 0.21 69.2 ± 10.9
Table 3.  Effect of isoflavones on inhibition (IC50) of the epoxide hydrolase (LTB4 generation) and 
aminopeptidase (PGP degradation) activities of LTA4H as described in Materials and methods. IC50 curves 
were generated from 3 technical replicates at each concentration of test compound and at least 2 biological 
replicates. Results depicted as mean ± SEM.
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with physiological levels of the enzyme found within the blood, whereas the Haeggstrom group have utilized 5 μ 
g/ml LTA4H. Whilst the merits of subtle differences in experimental methodologies can be argued, the direct 
side-by-side interrogation of compounds in identical assays, as performed in our study, enabled us to confidently 
assess relative potencies and selectivity of these drugs. To our mind ARM1 was the only compound tested that 
exhibited a marked selectivity between enzyme activities and thus represented the gold standard to which our 
novel drugs should be compared.
Subsequently, we have developed two distinct chemical series that exhibit the capacity to inhibit 
LTA4H-mediated LTB4 generation whilst demonstrating exquisite selectivity and leaving the aminopeptidase 
activity largely unperturbed. Compound 9 exhibited sub-μ M capacity to inhibit LTB4 generation in a cell based 
assay, whilst showing no inhibition of PGP degradation at 100 μ M – thus exhibiting a superior selectivity to 
ARM1 in our hands. Rationalizing this selective inhibition, X-ray crystallography demonstrated that compound 
9 formed a hydrogen bond with Asp-375. Previous site-directed mutagenesis studies have demonstrated that 
Asp-375 was absolutely required for hydrolysis of LTA4 into LTB4 but not for the peptidase activity – the only 
residue reported to be capable of making this distinction38. Whilst compound 9 exhibited a targeted potency and 
selectivity, preliminary studies suggest that it does not possess a suitable drug profile, being readily metabolized 
within microsomes. Thus whilst compound 9 represents a useful biological tool, further development would 
be mandatory to enhance in vivo stability. Subsequently, isoflavones were demonstrated to exhibit remarkable 
stability whilst still displaying a selective capacity to inhibit LTB4 generation. As a lead compound 15 was capable 
of inhibiting LTA4H epoxide hydrolase activity at the low μ M range with minimal inhibition of aminopeptidase 
activity. This could again be rationalized in part by a predicted interaction with key epoxide hydrolase residue 
Asp-375. Thus compound 15 also represents an exciting candidate for further drug development. Within the 
isoflavone series, compound 12 contains a catechol that is recognized as a PAINS substructure. However, as this is 
the only example of such a feature within the isoflavone series, the capacity of this class of compounds to inhibit 
LTB4 generation is clearly specific. Nonetheless, it would be prudent to be vigilant to the presence of PAINS sub-
structures in developing the isoflavone series towards the clinic.
Drug failures are common, multifactorial and often difficult to explain. In the case of LTA4H, however, the lack 
of clinical success could feasibly be attributable to the inadvertent inhibition of the enzyme’s anti-inflammatory 
aminopeptidase activity. Accordingly, the compounds identified within this study could act as starting points 
for the development of superior and safer LTA4H inhibitors to selectively target LTB4-mediated pathologies. 
However, whilst this study provides clear proof-of-concept for a rationalized selective LTA4H inhibitor, the 
compounds identified require significantly more optimization to generate inhibitors with a suitable drug profile 
that can be translated to the clinic. Clearly, there is a need to further assess the capacity of these compounds to 
inhibit LTB4 generation in a human cell based system, preferably with disease relevance. Furthermore, the studies 
detailed within this manuscript highlight the clear necessity to develop compounds with a superior ADMET/
DMPK profile, and we have not as yet assessed selectivity of these compounds – pertinent given the mandatory 
small size of the drugs. If these issues can be overcome, however, there is a clear rationale to test these classes of 
selective LTA4H inhibitors in pre-clinical animal models and ultimately the clinic.
Methods
Compound procurement. Compound 1 (Resveratrol; 3,4′ ,5-Trihydroxy-trans-stilbene; 5-[(1E)-2-(4-
Hydroxyphenyl)ethenyl]-1,3-benzenediol), compound 4 (Triacetyl resveratrol; (5-[(1E)-2-[4-(acetyloxy)phe-
nyl]ethenyl]-1,3-Benzenediol-1,3-diacetate, 3,5,4′ -Tri-O-acetylresveratrol), compound 5 (Pinostilbene hydrate; 
3,4′ -Dihydroxy-5-methoxy-trans-stilbene hydrate, 3-[(1E)-2-(4-hydroxyphenyl)ethenyl]-5-methoxyphenol 
hydrate), compound 10 (1-(2,4-Dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone) and compound 12 (7,8,4′ 
-trihydroxyisoflavone) were all purchased from Sigma Aldrich (Dorset, UK). Compound 2 (cis-Resveratrol) 
and compound 3 (trans-trismethoxy Resveratrol; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzene diol) were 
purchased from Cayman Chemicals (Michigan, USA). ARM1 (4-(4-benzylphenyl)-1,3-thiazole-2-amine), com-
pound 11 (7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one) and compound 13 (7-hydroxy-3-phenyl-4H-
chromen-4-one) were all purchased from VitasMLab (Kowloon, Hong Kong). SC57461A was purchased from 
Tocris Bioscience (Bristol, UK) and 4-Methoxydiphenylmethane (4-MDM) was purchased from Fluorochem, 
(Hadfield, UK). JNJ- 40929837 and DG-051 were synthesized by Peakdale Molecular (Derbyshire, UK) as pre-
viously described28,41. All other compounds were custom synthesized by Peakdale Molecular as described in 
Supplementary Information. ADMET (absorption, distribution, metabolism, and excretion – toxicity) studies 
were also outsourced to Peakdale Molecular.
Molecular Modelling. Structures were analysed and visualized using UCSF Chimera (1.9–1.10) and dock-
ing experiments were run using this implementation of AutoDock Vina. The 1.25 Å resolution X-ray structure 
of human LTA4H in complex with SC57461 (3U9W.pdb) was prepared by running Dock Prep to add hydrogens, 
charges, and correct incomplete sidechains. Ligands were built in Chimera and prepared using the inbuilt ligand 
preparation script. AutoDock Vina was configured to generate 9 binding modes; the “Exhaustiveness of search” 
parameter was unchanged from the default of 8 and the maximum energy score range allowed for poses was set 
to 3 kcal/mol. A box 15 × 8 × 15 Å was set up to define the receptor search volume and the results analyzed with 
ViewDock.
Ligand-protein structures were compared by aligning the protein chains of the reference and match struc-
ture(s) using MatchMaker as implemented in Chimera. Chimera is developed by the Resource of Biocomputing, 
Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS 
P41-GM103311).
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Crystallography methods. LTA4H (Novoprotein, NJ, USA) at 6 mg/ml in 10 mM Tris pH 8.0, 25 mM KCl 
was crystallized at 18 °C by hanging drop vapour diffusion against a reservoir of 20% PEG 8000, 0.1 M Sodium 
Acetate, 0.15 mM Imidazole pH7.8, 5 mM YbCl3. Crystals were transferred to drops containing well solution sup-
plemented with 20% (v/v) glycerol and saturating concentration (< 10 mM) of compound 9 for 3 hrs, before being 
flash frozen in liquid nitrogen. Data were collected on beamline I02 at Diamond Light Source (Oxfordshire, UK), 
and processed with Mosflm and Scala of the ccp4 suite42–44. The structure was solved using pdb 5AEN as an initial 
model and refined using refmac and phenix iterated with manual model building using coot45–47 to give a final 
structure with an Rfree of 19.6% and good geometry (Supplementary Table S2). A stereo image showing electron 
density around compound 9 is depicted in Supplementary Figure S2. The coordinates and structure factors for 
LTA4H:Compound 9 have been deposited in the protein databank (PDB ID 5N3W).
Mouse procedures. This study was carried out in accordance with the recommendations in the Guide for 
the Use of Laboratory Animals of Imperial College London. All animal procedures and care conformed strictly 
to the UK Home Office Guidelines under the Animals (Scientific Procedures) Act 1986, and the protocols were 
approved by the Home Office of Great Britain. Six- to eight-week-old female BALB/c mice were purchased from 
Harlan Olac Ltd (Oxon, UK). All mice were kept in specified-pathogen-free conditions and provided autoclaved 
food, water and bedding.
For murine ex vivo analysis of LTB4 production and PGP degradation, SC57461A (in physiological saline with 
2% DMSO and 1% Tween 80), JNJ-40929837 (in 20% HPβ CD) or relative vehicle controls were administered 
orally (10 mg/kg) to female BALB/c mice. Blood was obtained from mice 4 h after oral dosing and downstream 
analysis performed blinded by an independent researcher. To assess inhibition of epoxide hydrolase activity, 
blood (90 μ l added to 10 μ l 500 U/ml heparin) was diluted 1:1 in RPMI 1640 medium, after which 200 μ l aliquots 
of the diluted blood were added to a microtiter plate. Calcium ionophore A-23187 (20 μ g/ml final concentration) 
was added and the mixture incubated 20 min at 37 °C in a humidified incubator. The reaction was terminated by 
centrifugation (600 × g, 5 min, 4 °C). Supernatants were analyzed for LTB4 by EIA (see below). To assess inhibi-
tion of aminopeptidase activity, PGP degrading capacity of serum was assessed as detailed below. Furthermore, 
absolute concentrations of PGP in serum was determined as detailed below.
Cell isolation. To isolate murine bone marrow neutrophils, the femur and the tibia from both hind legs were 
removed and freed of soft tissue attachments, and the extreme distal tip of each extremity cut off. HBSS contain-
ing 15 mM EDTA and 30 mM HEPES was forced through the bone with a syringe. After dispersing cell clumps 
and passage through a 100 μ M sieve (BD labware, New Jersey), red blood cells were lysed by resuspending pel-
lets in ACK buffer (for 3 minutes at room temperature) before centrifugation (800 × g, 5 min) and washing with 
HBSS. The cell suspension was centrifuged (800 × g, 5 min, 4 °C) and resuspended in RPMI. The cells were layered 
onto a 72%, 64%, 52% Percoll gradient (Sigma-Aldrich, UK) diluted in PBS (100% Percoll = nine parts Percoll 
and one part 10x PBS), and centrifuged (1500 × g, 30 min, room temperature) without braking. The neutrophils 
at the 64%/72% interface were harvested and washed with 20 ml RPMI. Cell viability was assessed by trypan blue 
exclusion and confirmed to be > 90% neutrophils by flow cytometry.
To isolate human neutrophils, peripheral blood was taken from healthy volunteers following informed con-
sent and according to an approved protocol. Neutrophils were subsequently isolated using the MACSxpress™ 
Neutrophil Isolation Kit (Miltenyi Biotec, UK).
Flow cytometry. Single-cell suspensions were stained for surface markers in PBS containing 0.1% sodium 
azide and 1% BSA for 30 min at 4 °C and fixed with 2% paraformaldehyde. Data was acquired on a BD FACS 
Fortessa machine (BD Biosystems, UK). Forward scatter and side scatter gates were used to exclude debris and 
dead cells were excluded using a fixable near IR dead cell stain kit for 633 or 635 nm excitation. Neutrophils were 
defined as Ly-6Ghigh (Ly6G-FITC; BD Biosciences; clone 1A8), CD11bhigh (CD11b-PerCP; eBioscience; clone 
M1/70), CD11clow (CD11c-APC; BD Biosciences; clone HL3), F4/80low (F4/80-PE/Dazzle; BD Biosciences; clone 
BM8).
Liquid chromatography-electrospray-ionization-tandem mass spectrometry (ESI-LC/MS/MS) 
for PGP detection. For peptide quantification in serum, PGP and AcPGP were measured using a 
MDS Sciex API-4000 spectrometer (Applied Biosystems, Foster City, CA) equipped with a Shimadzu HPLC 
(Columbia, MD). For peptide quantification from degradation experiments, PGP and AcPGP were measured 
using a Thermo Accela Pump and Autosampler coupled to a Thermo TSQ Quantum Access. HPLC was done 
using a 2.0 × 150 mm Jupiter 4u Proteo column (Phenomenex, Torrance, CA) with A: 0.1% HCOOH and B: 
MeCN + 0.1% HCOOH: 0 min–0.5 min 5% buffer B/95% buffer A, then increased over 0.5–2.5 min to 100% 
buffer B/0% buffer A. Background was removed by flushing with 100% isopropanol/0.1% formic acid. Positive 
electrospray mass transitions were at 270–70, 270–116 and 270–173 for PGP and 312–140 and 312–112 of AcPGP. 
Peak area was measured, and PGP/AcPGP peptide concentrations were calculated using a relative standard curve 
method as previously described11.
Assessment of LTA4H aminopeptidase activity. Mouse serum (diluted 1/10 in PBS) or recombinant 
human LTA4H (0.1 μ g/ml; Cayman Chemicals, Michigan, USA) were incubated with 0.4 mM PGP at 37 °C in 5% 
CO2 for varying periods of time. Concentrations of PGP remaining were subsequently quantified by ESI-LC/MS/
MS (as discussed above) by comparison with PGP standards. The percentage of peptide degraded was determined 
relative to control samples of 0.4 mM PGP alone. PGP degradation was also assessed by measurement of free 
proline released and its ensuing reaction with Ninhydrin (as discussed below). Test compounds were assayed in a 
blinded manner by an investigator during determination of the effect on LTA4H aminopeptidase activity.
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To assess free proline liberated, aliquots from PGP degradation experiments were diluted 1 in 10 in PBS (to 
a final volume of 250 μ l). Glacial acetic acid (250 μ l) was then added, followed by 250 μ l of ninhydrin solution 
(25 mg/ml in acetic acid/6 M phosphoric acid; heated at 70 °C to dissolve). The reaction mixture was heated at 
100 °C for 60 minutes, allowed to cool to room temperature and the proline containing fraction extracted with 
500 μ l of toluene and optical density measured at 520 nm.
Assessment LTA4H epoxide hydrolase activity. 1 × 105 murine bone marrow-derived neutrophils or 
human blood-derived neutrophils (compound 9 only) in 100 μ l of RPMI were treated with A23187 at a final 
concentration of 20 μ g/ml. 1% DMSO was used as a control. Cells were incubated for 20 minutes at 37 °C, and the 
reaction was terminated by centrifugation (600 × g, 5 min, 4 °C). Supernatants were removed and stored at − 80 °C 
for subsequent LTB4 analysis. The concentration of LTB4 generated in the epoxide hydrolase activity assay was 
assayed using an EIA, according to manufacturer’s directions (R&D systems, Minneapolis, MN). Test compounds 
were assayed in a blinded manner by an investigator during determination of effect on LTA4H epoxide hydrolase 
activity.
Statistical analysis. Data were analyzed using Prism 4 (GraphPad Software Inc. La Jolla, CA, USA). Data 
was non-parametric and statistical significance was calculated using an unpaired Mann-Whitney test (two-tailed). 
All p-values of ≤ 0.05 (*) and ≤ 0.01 (**) were considered significant and are referred to as such in the text.
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